Prevention of thrombosis in polycythemia vera and essential thrombocythemia

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera

“…84 Whether the site of first thrombosis should be the primary determinant in choosing further antithrombotic therapy is unclear and would need to be further clarified in large wellcontrolled studies. 38 Recent guidelines therefore recommend oral anticoagulation in venous thrombosis for 3 -6 months in PV and ET patients. 4 An important exception is the diagnosis of splanchnic vein thrombosis, where life-long oral anticoagulation is recommended.…”

“…6 However, additional risk factors have also been established, and alternative risk stratification systems have been proposed. 38 Among the other described general risk factors are hypercholesterolemia, 39 smoking 40,41 and diabetes mellitus 41 ( Table 3). As seen in Table 3, the thrombotic risk seems to be more related to patient characteristics (age, previous thrombosis and cardiovascular risk factors) than to the disease itself.…”

Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation

“…A simplified method to assess this risk and the recommendations for the use of available drugs have been recently reported elsewhere. 75 An appropriate treatment of blood hyperviscosity in PV patients is essential and can be performed with phlebotomies in patients with low thrombotic risk whereas in subjects at increased thrombotic risk, hydroxyurea (HU) is the treatment of choice. The high antithrombotic efficacy of HU has been recently shown also in ET.…”

Philadelphia-negatív krónikus myeloproliferativ neoplasia regiszter magyarországi létrehozása

“…A Harrison által összegzett stratifikáció [7] azonban nem részletezi a komplex cardiovascularis rizikóstátuszra vonatkozó adatokat. Ebből kiindulva, a regiszter kialakí-tása során a Landolfi-kritériumok bevezetését tartottuk fontosnak (1. táblázat) [8]. A Landolfi-kritériumok a thromboticus anamnézis mellett a fehérvérsejt-, thrombocytaszámra, a magas vérnyomásra, a magas lipidszintekre, a dohányzásra és a diabetesre vonatkozó adatokra is figyelmet fordít.…”

“…A Landolfi-kritériumok a thromboticus anamnézis mellett a fehérvérsejt-, thrombocytaszámra, a magas vérnyomásra, a magas lipidszintekre, a dohányzásra és a diabetesre vonatkozó adatokra is figyelmet fordít. A rizikóstátusz alapján PV-ben, ETben a terápia egyértelműen meghatározható (2. táblá-zat) [8]. A kitűzött célok elérését szolgáló regiszter kialakítása kapcsán figyelembe vettük a magyarországi munkacsoportok által tett ajánlásokat is [9,10].…”